Treatment of patients with unresectable squamous head and neck cancer with induction chemotherapy followed by hyperfractionated radiotherapy

Cancer/Radiotherapie

Volumn 12, Issue 2, 2008, Pages 88-95

  Mesia R ^a   Majem, M ^a   Barretina Ginesta, M P ^a   Galiana, R ^a   Manos M ^a   Guedea, F ^a   Montes, A ^a   Monner, A ^a   Perez J ^a   Cardenal, F ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Hyperfractionated radiotherapy; Induction chemotherapy; Unresectable squamous head and neck cancer

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DEMENTIA; DIARRHEA; DISEASE SEVERITY; DRUG FATALITY; EMERGENCY SURGERY; EPITHELIUM; FOLLOW UP; HEAD AND NECK CANCER; HEART MUSCLE ISCHEMIA; HUMAN; HYPOPHARYNX CARCINOMA; ISCHEMIA; KIDNEY DYSFUNCTION; LARYNX CARCINOMA; LARYNX EDEMA; MAJOR CLINICAL STUDY; MOUTH CARCINOMA; MUCOSA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RADIATION NECROSIS; RADIOTHERAPY; SOFT TISSUE; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TISSUE NECROSIS; TRACHEOTOMY; TREATMENT RESPONSE; TUMOR LOCALIZATION;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED;

EID: 41549136596     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2007.09.148     Document Type: Article

References (44)

1. Adelstein D.J., Li Y., Adams G.L., Wagner Jr. H., Kish J.A., Ensley J.F., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J. Clin. Oncol. 21 (2003) 92-98
2. Al-Sarraf M., LeBlanc M., Giri P.G., Fu K.K., Cooper V., Vuong T., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J. Clin. Oncol. 16 (1998) 1310-1317
3. Bernier J., Coens C., Remenar E., Van Herpen C., Germa Lluch J., Stewart S., et al. Impact on quality of life of the addition of docetaxel to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced unresectable squamous cell carcinoma of the head and neck: an EORTC study 24971. Proc. Am. Soc. Clin. Oncol. 24 (2006) 285s
4. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
5. Brizel D.M., Albers M., Fisher S.R., Scher R.L., Richtsmeier W.J., Hars V., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 338 (1998) 1798-1804
6. Brocksein B.E., Haraf D.J., Kies M., et al. Reduction of distant metastases in head and neck cancer with concomitant chemotherapy. J. Clin. Oncol. (2000) 3320-3321
7. Calais G., Alfonsi M., Bardet E., Sire C., Germain T., Bergerot P., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. 91 (1999) 2081-2086
8. Calais Y., Pintreau M., Alfonsi C., Sire C., Tuchais C., Tortochaux J., et al. Randomized phase III trial comparing induction chemotherapy using cisplatin, 5-fluorouracil with or without docetaxel for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-2001. Proc. Am. Soc. Clin. Oncol. 24 (2006) 280s
9. Colevas A.D., Norris C.M., Tishler R.B., Fried M.P., Gomolin H.I., Amrein P., et al. Phase II trial of docetaxel, cisplatin, fluorouracil and leucovorin as induction for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 17 (1999) 3505-3511
10. Cummings B.J., Keane T.J., and Pintilie M. A prospective randomized trial of hyperfractionated versus conventional once daily radiation for advanced aquamous cell carcinoma of the pharynx. Int. J. Radiat. Oncol. Biol. Phys. 35 (1996) 235 (1996)
11. Dische S., Saunders M., Barrett A., Harvey A., Gibson D., and Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother. Oncol. 44 (1997) 123-136
12. Forastiere A.A., Goepfert H., Maor M., Pajak T.F., Weber R., Morrison W., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 349 (2003) 2091-2098
13. Forastiere AA, Maor M, Weber RS, Pajak T, Glisson B. Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx. Induction Cisplatin/5FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings art I. Vol 24, No 18S, 2006:5517.
14. Fortin A, Albert M, Eric V, Josee A. Histologic grade as an independent predictor of distant metastases in head and neck cancers. Proc ASCO 2000;19:411a (A1647); 2000.
15. Fu K.K., Pajak T.F., Trotti A., Jones C.U., Spencer S.A., Phillips T.L., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys. 48 (2000) 7-16
16. Galiana R., Boladeras A., Mesia R., Gomez J., de Juan A., Manos M., et al. Twice-a-day radiotherapy for head and neck cancer: the Catalan Institute of Oncology experience. Radiother. Oncol. 64 (2002) 19-27
17. In: Hermanek P., and Sobin L.H. (Eds). International Union Against Cancer (UICC). TNM classification of malignant tumors. 4th edition (1987), Springer-Verlag, Heidelberg (Germany
18. Hitt R., Lopez Pousa A., Rodriguez M., Escrig V., Carles J., Rizo A., et al. Phase III study comparing cisplatin and 5-fluoruracil versus cisplatin, 5-fluoruracil and Paclitaxel as induction therapy in locally advanced head and neck cancer. J. Clin. Oncol. (2005) 8636-8645
19. Hitt R., Paz-Ares L., Brandariz A., Castellano D., Pena C., Millan J.M., et al. Induction chemotherapy with paclitaxel, cisplatin, and 5-fluorouracil for squamous cell carcinoma of the head and neck: long term results of a phase II trial. Ann. Oncol. 13 (2002) 1665-1673
20. Horiot J.C., Bontemps P., Van den Bogaert W., Le Fur R., van den Weijngaert D., Bolla M., et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother. Oncol. 44 (1997) 111-121
21. Horiot J.C., Le Fur R., N'Guyen T., Chenal C., Schraub S., Alfonsi S., et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother. Oncol. 25 (1992) 231-241
22. Huguenin P., Beer K.T., Allal A., Rufibach K., Friedli C., Davis J.B., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J. Clin. Oncol. 22 (2004) 4665-4673
23. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N. Engl. J. Med. 324 (1991) 1685-1690
24. Jeremic B., Shibamoto Y., Milicic B., Nikolic N., Dagovic A., Aleksandrovic J., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J. Clin. Oncol. 18 (2000) 1458-1464
25. Kaplan E.L., and Meier P. Nonparametric estimation for incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
26. Kotz T., Costello R., Li Y., and Posner M.R. Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck 26 (2004) 365-372
27. Lefebvre J.L., Chevalier D., Luboinski B., Kirkpatrick A., Collette L., and Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl. Cancer Inst. 88 (1996) 890-899
28. León X., Lopez-Pousa A., de Vega M., Del Prado Venegas M., Orus C., Kolanczak K., et al. Results of an organ preservation protocol with induction chemotherapy and radiotherapy in patients with locally advanced laryngeal carcinoma. Eur. Arch. Otorhinolaryngol. 262 (2005) 93-98
29. Lin J.C., Jan J.S., Hsu C.Y., Liang W.M., Jiang R.S., and Wang W.Y. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J. Clin. Oncol. 21 (2003) 631-637
30. Majem M., Mesía R., Mañós M., Gomez J., Galiana R., Cardenal F., et al. Does induction chemotherapy still have a role in larynx preservation strategies? The experience of Institut Català d'Oncologia in stage III larynx carcinoma. Laryngoscope 116 (2006) 1651-1656
31. Merlano M., Benasso M., Corvo R., Rosso R., Vitale V., Blengio F., et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J. Natl. Cancer Inst. 88 (1996) 583-589
32. Nguyen N.P., Moltz C.C., Frank C., Vos P., Smith H.J., Karlsson U., et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann. Oncol. 15 (2004) 383-388
33. Paccagnella A., Orlando A., Marchiori C., Zorat P.L., Cavaniglia G., Sileni V.C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J. Natl. Cancer Inst. 86 (1994) 265-272
34. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355 (2000) 949-955
35. Pinto L.H., Canary P.C., Araujo C.M., Bacelar S.C., and Souhami L. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 21 (1991) 557-562
36. Posner M.R., Glisson B., Frenette G., Al-Sarraf M., Colevas A.D., Norris C.M., et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol. 19 (2001) 1096-1104
37. Posner M.R., Hershock D.M., Blajman C.R., Mickiewicz E., Winquist E., Gorbounova V., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. NEJM 357 (2007) 1705-1715
38. Robert F., Ezekiel M.P., Spencer S.A., Meredith R.F., Bonner J.A., Khazaeli M.B., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19 (2001) 3234-3243
39. Urba S.G., Wolf G., Bradford C.R., Thornton A.F., Eisbruch A., Terrell J.F., et al. Neoadjuvant therapy for organ preservation in head and neck cancer. Laryngoscope 110 (2000) 2074-2080
40. Vermorken J.B., Remenar E., Van Herpen C., Gorlia T., Mesia R., Regardin M., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. NEJM 357 (2007) 1695-1704
41. Vokes E.E., Kies M.S., Haraf D.J., Stenson K., List M., Humerickhouse R., et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J. Clin. Oncol. 18 (2000) 1652-1661
42. Wendt T.G., Grabenbauer G.G., Rodel C.M., Thiel H.J., Aydin H., Rohloff R., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J. Clin. Oncol. 16 (1998) 1318-1324
43. Winquist E., Oliver T., and Gilvert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck 29 (2007) 38-46
44. World Health Organization. Handbook for reporting results of cancer treatment. WHO offset publication no. 48 (1979), Switzerland, Geneva